Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)

Abstract

Purpose The aim was to develop and update a guideline which would improve the quality of care offered to women with gestational and non-gestational trophoblastic disease, a group of diseases characterized by their rarity and biological heterogeneity.

Methods In accordance with the method used to compile S2k-guidelines, the guideline authors carried out a search of the literature (MEDLINE) for the period 1/2020 to 12/2021 and evaluated the recent literature. No key questions were formulated. No structured literature search with methodical evaluation and assessment of the level of evidence was carried out. The text of the precursor version of the guideline from 2019 was updated based on the most recent literature, and new statements and recommendations were drafted.

Recommendations The updated guideline contains recommendations for the diagnosis and therapy of women with hydatidiform mole (partial and complete moles), gestational trophoblastic neoplasia after pregnancy or without prior pregnancy, persistent trophoblastic disease after molar pregnancy, invasive moles, choriocarcinoma, placental site nodules, placental site trophoblastic tumor, hyperplasia at the implantation site und epithelioid trophoblastic tumor. Separate chapters cover the determination and assessment of human chorionic gonadotropin (hCG), histopathological evaluation of specimens, and the appropriate molecular pathological and immunohistochemical diagnostic procedures. Separate chapters on immunotherapy, surgical therapy, multiple pregnancies with simultaneous trophoblastic disease, and pregnancy after trophoblastic disease were formulated, and the corresponding recommendations agreed upon.

Key words

guideline - trophoblastic disease - trophoblastic neoplasia - molar pregnancy - choriocarcinoma

• References/Literatur

• 1 Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol 2007; 19: 486-491
• 2 Garner EI, Goldstein DP, Feltmate CM. et al. Gestational trophoblastic disease. Clin Obstet Gynecol 2007; 50: 112-122
• 3 Hui P, Baergen R, Cheung A, Fukunaga M, Gersell D, Lage J, Ronnett B, Sebire N, Wells M. Gestational trophoblastic Disease. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH. eds. WHO Classification of Tumours of female reproductive Organs. Lyon: IARC; 2014: 158-167
• 4 Savage P, Williams J, Wong SL. et al. The demographics of molar pregnancies in England and Wales from 2000–2009. J Reprod Med 2010; 55: 341-345
• 5 Tham BW, Everard JE, Tidy JA. et al. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. BJOG 2003; 110: 555-559
• 6 Eysbouts YK, Bulten J, Ottevanger PB. et al. Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol 2016; 140: 70-75
• 7 Ngan HY, Bender H, Benedet JL. et al. FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 2003; 83 (Suppl. 01) 175-177
• 8 Sebire NJ, Foskett M, Paradinas FJ. et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 2002; 359: 2165-2166
• 9 Lin LH, Maesta I, Braga A. et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol 2017; 145: 88-95
• 10 Suksai M, Suwanrath C, Kor-Anantakul O. et al. Complete hydatidiform mole with co-existing fetus: Predictors of live birth. Eur J Obstet Gynecol Reprod Biol 2017; 212: 1-8
• 11 Zilberman Sharon N, Melcer Y, Maymon R. Is a Complete Hydatidiform Mole and a Co-existing Normal Fetus an Iatrogenic Effect?. Isr Med Assoc J 2019; 21: 653-657
• 12 Ghorani E, Kaur B, Fisher RA. et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet 2017; 390: 2343-2345
• 13 Choi MC, Oh J, Lee C. Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. Eur J Cancer 2019; 121: 94-97
• 14 You B, Bolze PA, Lotz JP. et al. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. J Clin Oncol 2020; 38: 3129-3137
• 15 Gadducci A, Lanfredini N, Cosio S. Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia. Gynecol Endocrinol 2015; 31: 673-678
• 16 Tranoulis A, Georgiou D, Sayasneh A. et al. Gestational trophoblastic neoplasia: a meta-analysis evaluating reproductive and obstetrical outcomes after administration of chemotherapy. Int J Gynecol Cancer 2019; 29: 1021-1031
• 17 Garcia MT, Lin LH, Fushida K. et al. Pregnancy outcomes after chemotherapy for trophoblastic neoplasia. Rev Assoc Med Bras (1992) 2016; 62: 837-842
• 18 Gadducci A, Cosio S, Fanucchi A. et al. Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. Anticancer Res 2016; 36: 3477-3482
• 19 Wong JM, Liu D, Lurain JR. Reproductive outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia. J Reprod Med 2014; 59: 204-208